Latest Industry Insights

From increasing trial diversity to using plants to manufacture drugs, the experts weigh in.

To find out more about the Taiwan Precision Medicine Initiative and its aim to implement a sustainable precision health ecosystem in Taiwan, we spoke to Dr. Pui-Yan Kwok, leader of the initiative.

We spoke to Darlene Solomon to learn more about improving sustainability in science and Agilent’s commitment to My Green Lab and other sustainability initiatives.

There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.

In this interview, CEO of Arrayjet Dr. Iain McWilliam discusses advancements in modern microarray technology and the benefits that these tools can provide for high-throughput screening.

This article spotlights the driving forces behind Basel’s snowballing reputation, and notes some of the success stories arising from this innovative biotech powerhouse.

In this interview, we learn more about the support available for entrepreneurs looking to take their ideas from the bench to viable business.

In this opinion piece, Daniel Elgort takes a look at how bioinformatics has already shaped the cancer care landscape and how its role will continue to grow over time.

This article discusses the importance of data lineage and traceability for academic labs looking to maximize their publishing potential.

In this article, we explore how equipment, laboratory and experimental approaches can accelerate failure so companies change and adjust their approach before it’s too late.